Industry Veteran Combines Expertise with Passion for Healthcare
MIAMI, Nov. 14 /PRNewswire/ -- Novis Pharmaceuticals, a leading distributor of biotherapeutic products to healthcare providers funded by MTS Health Investors and Oaktree Capital Management, L.P., announced today the appointment of Thomas E. Burke III to the position of President and CEO. Tom brings over 30 years of distribution experience to Novis Pharmaceuticals, with extensive functional expertise in sales, sales management, operations and the management and development of people.
As the Group Vice-President of Cardinal Health, Integrated Provider Solutions, Tom had Northeast responsibility for five businesses: Distribution, Laboratory, Manufactured Products, Pyxis Supply and Presource which generated $1.4 billion in revenue. He also held several executive level positions in other Cardinal Health companies, including serving as President of the Southeast and the Northeast Regions of Cardinal Health, Medical Products and Services, each with revenue in excess of $1.3 billion and consisting of seven distribution facilities. In addition, Tom was responsible for a two-facility region that represented $3.1 billion in pharmaceutical sales for Cardinal Distribution/Aurora, Illinois Division when he held the position of Regional Vice President.
Jay J. Levin, Executive Chairman of Novis Pharmaceuticals, said, "Novis is committed to providing industry-leading standards of quality and exceptional service to our customers. We were looking for an innovative and visionary leader who not only had the depth of functional expertise to grow the business and to develop our people, but also the personal integrity and character to build sustainable and mutually-rewarding relationships with our manufacturers, our supply chain partners, and our customers."
"I am honored to have worked my entire career in an industry that makes a difference in patients' lives," added Tom Burke. "In order for Novis Pharmaceuticals to succeed, we know we must deliver flawlessly every time. We know that we can save a life every time one of our products is used. There is no room for error."
For more information about Novis Pharmaceuticals, please visit http://www.novispharma.com.
About NOVIS Pharmaceuticals
Novis Pharmaceuticals is a leading national distributor of some of the world's leading plasma-derived products such as albumin, immune globulin, hyperimmunes and anti-hemophilic Factors VII, VIII and IX. Hospitals, home infusion therapy companies and other healthcare providers use these biotherapeutics to treat trauma, autoimmune conditions, immune deficiencies, infectious diseases, bleeding disorders, and other life-threatening conditions.
MTS Health Investors, LLC, located in New York, is a healthcare private equity firm that makes equity investments in the buyout, recapitalization or growth financing of healthcare operating companies. MTS focuses on businesses that operate in services sectors of the healthcare industry - managed care/health insurance, providers of healthcare services, distributors of medical products and providers of outsourced services to the healthcare industry. The firm also invests in manufacturers of low-technology medical products. For further information, please visit: http://www.mtshealthinvestors.com.
About Oaktree Capital Management, L.P.
Oaktree Capital Management was founded in 1995 and is headquartered in Los Angeles, California. It is an independent investment management firm with over $52 billion of assets under management in specialized investment strategies. These strategies include private equity, distressed debt, high yield bonds, convertible securities, Asian and emerging market equities, real estate, and mezzanine debt. Oaktree's institutional clients include Fortune 100 companies, large public pension funds, university endowments, private foundations and high net worth individuals. In addition to Los Angeles, Oaktree has offices in New York, Stamford, Tokyo, Singapore, Hong Kong, Beijing, London, Frankfurt and, through fund affiliates, Luxembourg.
|SOURCE Novis Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved